Medical News

RSS

Today's opinions and editorials

Taxing high-cost insurance plans to fund health care reform is a bad idea. In fact, it could threaten the medical insurance plans of middle-class workers who obtain coverage from their employers (Gerald W. McEntee, 9/28).

28 Sep 2009

Government plans intense monitoring for swine flu vaccine side effects

Although health officials say they have no reason to expect any unusual problems with the vaccine that will likely be available next month, the government is establishing an extensive tracking system to watch for possible side effects, the Associated Press/Washington Post report.

28 Sep 2009

UNC awarded $8.6M for a new Center for Integrated Systems Genetics

Autism, depression, anxiety. Antipsychotic drug side effects. What are the genetic and environmental factors that underlie and contribute to these complex problems? And how do genes and environment interact to shape them?

28 Sep 2009

MarkMonitor Brandjacking Index reveals growth in pharmaceutical brandjacking for popular drug brands

MarkMonitor®, the global leader in enterprise brand protection, today released the company’s latest Brandjacking Index®, which finds a parallel online system of pharmaceutical supply and demand fueled by continued growth in listings for pharmaceuticals on business-to-business (B2B) exchange sites as well as increased traffic to illicit pharmacies. The report also reveals a growth in pharmaceutical brandjacking for popular drug brands.

28 Sep 2009

Administration officials court key lawmakers on health care

Administration officials are increasingly courting key stakeholders on health care. The New York Times reports: "After months of cutting deals and stroking drug makers, hospitals and doctors, the president's aides are laying the groundwork for a final round of Congressional arm-twisting. ... One Democrat who consults frequently with the White House said that a main goal of the administration has been to prevent any Democrat from publicly declaring opposition to the measure."

28 Sep 2009

Nuance launches eScription version 9 for for computer aided medical transcription

Nuance Communications, Inc., a leading supplier of speech solutions, today announced the availability of version 9 of its eScription on-demand platform for computer aided medical transcription (CAMT), a solution used by healthcare organizations to increase productivity and save costs associated with medical transcription (MT).

28 Sep 2009

The CDH Proton Therapy Center announces arrival of a 220-ton cyclotron for treating cancer

A 220-ton cyclotron, the core of what will soon be Illinois’ most advanced radiation treatment center, has ended a 5,000-mile journey that began in Belgium, arriving at the construction site of the CDH Proton Therapy Center, a ProCure Center, located in suburban Warrenville. Capable of accelerating protons, the cyclotron is the core piece of equipment used in proton therapy, an alternative to X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

28 Sep 2009

Private health system takes root in British Columbia

The Los Angeles Times reports that consumers in Canada are "beginning to flirt with private-sector medicine."

28 Sep 2009

Preclinical data of CardiAQ Valve Technologies' TMVI in vivo study presented at the TCT 2009

Transcatheter heart valve company CardiAQ Valve Technologies (CVT), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that successful results of an acute in vivo study of its TMVI system were disclosed by Dr. Joseph Bavaria during the “Mitral Valve Therapies Prior to and in Human Investigation” program at the “Transcatheter Cardiovascular Therapeutics (TCT) 2009” annual scientific meeting on Friday.

28 Sep 2009

The Children’s Hospital implements Eclipsys’ integrated decision support and analysis solution

Eclipsys Corporation®, The Outcomes Company®, today announced that pediatric hospitals are emerging as a key client base for its Sunrise EPSi™ integrated suite of business performance management solutions. In face of declining reimbursements, both acute and specialty care organizations are seeking the decision support solution as an effective means to become more efficient and improve productivity without sacrificing quality.

28 Sep 2009

World’s first Cesium-131 implant for recurrent head and neck cancer performed

IsoRay, Inc. (Amex: ISR) announced today that on August 5, 2009, Dr. Bhupesh Parashar from the Department of Radiation Oncology, Dr. David Kutler of the Department of Otorhinolaryngology, and Dr. Jason Spector of the Department of Plastic Surgery at Weill Cornell Medical Center performed the world’s first Cesium-131 implant for a recurrent head and neck cancer (buccal mucosa).

28 Sep 2009

PolyMedix receives patent protection for computational methods in the design of amphiphilic polymers

PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has received patent protection for certain exclusively licensed intellectual property by the issuance to the University of Pennsylvania of U.S. patent number 7,590,517, “Methods, Systems, and Computer Program Products for Computational Design of Amphiphilic Polymers.”

28 Sep 2009

Excelsior's SwabCap launched at the 23rd Association for Vascular Access conference

Excelsior Medical, one of the leading manufacturers of pre-filled catheter flush syringes and syringe pump systems, announced that it has launched a major new product: the SwabCap™ Luer Access Valve Disinfection Cap.

28 Sep 2009

Merck to distribute Afluria in the U.S. for CSL Biotherapies

CSL Biotherapies and its parent company, CSL Limited, one of the world's leading manufacturers of influenza vaccine, have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria® in the United States under an exclusive, six-year agreement effective September 3, 2009.

28 Sep 2009

Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs

Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.

28 Sep 2009

Correlagen Diagnostics to develop diagnostic tests on the Helicos Genetic Analysis Platform

Helicos BioSciences Corporation (NASDAQ: HLCS) today announced the sale of a system and a scientific collaboration with Correlagen Diagnostics Inc., a leading provider of genetic tests for disease diagnosis.

28 Sep 2009

IOF awards the Linda Edwards Memorial Award to AFI

The International Osteoporosis Foundation (IOF) has awarded its prestigious 'IOF Linda Edwards Memorial Award' to the Arthritis Foundation of India Trust (AFI), one of 193 IOF member societies around the world. The award was presented today at the IOF Worldwide Osteoporosis Patient Society Conference, being held from September 22-25, 2009 in Beijing, China.

28 Sep 2009

European Commission grants conditional marketing authorization for Gilead's Cayston

Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.

28 Sep 2009

First edition: September 28, 2009

A look at today's headlines reveals that specific issues regarding the health overhaul effort continue to get significant attention and trigger debate.

28 Sep 2009

Correlagen to use Helicos Genetic Analysis System for diagnosing genetic disorders

Correlagen Diagnostics Inc., a leading provider of genetic testing for disease diagnosis, today announced the acquisition of a system from and a scientific collaboration with Helicos BioSciences Corporation.

28 Sep 2009

Medical News

Today's opinions and editorials

Government plans intense monitoring for swine flu vaccine side effects

UNC awarded $8.6M for a new Center for Integrated Systems Genetics

MarkMonitor Brandjacking Index reveals growth in pharmaceutical brandjacking for popular drug brands

Administration officials court key lawmakers on health care

Nuance launches eScription version 9 for for computer aided medical transcription

The CDH Proton Therapy Center announces arrival of a 220-ton cyclotron for treating cancer

Private health system takes root in British Columbia

Preclinical data of CardiAQ Valve Technologies' TMVI in vivo study presented at the TCT 2009

The Children’s Hospital implements Eclipsys’ integrated decision support and analysis solution

World’s first Cesium-131 implant for recurrent head and neck cancer performed

PolyMedix receives patent protection for computational methods in the design of amphiphilic polymers

Excelsior's SwabCap launched at the 23rd Association for Vascular Access conference

Merck to distribute Afluria in the U.S. for CSL Biotherapies

Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs

Correlagen Diagnostics to develop diagnostic tests on the Helicos Genetic Analysis Platform

IOF awards the Linda Edwards Memorial Award to AFI

European Commission grants conditional marketing authorization for Gilead's Cayston

First edition: September 28, 2009

Correlagen to use Helicos Genetic Analysis System for diagnosing genetic disorders

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News